Matt. Good all for us. joining you you, Thank thank afternoon, and
first two XXX(k) FDA we providing devices important product innovative time the clearance an Pantheris new new for was for and received year, business a increasing quarter Avinger Tigereye basis X% this exciting second sequential our in a sales new in quarter ST quarter, to had opportunity for on launches resource of The LV, revenue good half in adding as and Avinger. two by for the second the our team. momentum second We
are products will meaningful growth We these business new for half we year. the introduction opportunities second our the confident that through move two of as the PAD of provide
these X platform, new product product simplified providing most our coronary image-guided a us HD build-out two high-value with more of imaging the console, solution the application. superior, By we first on for for inroads the advanced our completes new the believe catheter certain image-guided our coronary coronary systems development a proprietary market. efforts our we to launch market R&D disease CTOs, providing to leveraging Combined Lightbox we peripheral crossing of condition of the focus challenging and of artery redefine believe can first allowing portfolio, our and Avinger's
to the clinical an investigational we candidates design from of on studies study of progress or during with specialists animal first this valuable stage for progress, allow to in initiative XXXX. significant this With the initiation advancing the on we preparing quarter, animal remain in through track the of a round quarter. feedback next application for incorporating trials, made half believe and We the file FDA IDE device year this exemption CTO first second of next coronary
our excellent progress new product solid metrics. initiatives, reported made on we operating also we While
we quarter, our revenue existing head efficient EBITDA expanded during sales hired operating four to ago significant and case cost both per coverage specialists During or for held year improvement at the quarters. in strong period. second and margin remained adjusted driving in capability quarter members. the quarter, clinical we XX% future maintained to our productivity additional compared Sales gross the prior team model, provide And to
received Let Tigereye cleared limited high-speed April me for take We recently a in our clearance few launch minutes to in XXX(k) ST provide our CTO-crossing on catheter further new and products. peripheral updates initiated May. two
Since time, nine than have sites completed the with that more at new XX system. physicians cases
We over have both existing launch support an and the additional expect cases into next limited sold to to catheters month. in our activities additional sites and sites, complete five these
physician later positive so with launch, year. broader Based on plans our we've the to far, consistent completed preparations full the for team success reliability, communicated expansion cases sales clinical and training this product begun feedback product quarter, this the inventory commercial and from building earlier
As crossing, or help CTOs, a at during cross high-definition below them true up above occlusions peripheral arteries a for blocked Tigereye the total knee. the low-profile, guide vasculature ST stay highly is imaging in French which to the real-time valuable is Tigereye to five both X,XXX lumen for OCT during chronic provides and spins the RPM to designed physician reminder, and which beneficial speeds the completely procedure, patient. the in information ST and are treatment providing system
to aid procedural during Tigereye the with catheter morphology. exceptionally our has procedure, It design interpretation to power crossing in configuration and precisely imaging features in performs multiple tip ST the image increase adds well in upgrades a during success shaft advanced treatment, Lightbox platform. incorporates to and also and and design user-controlled X direct catheter the deflectable tip challenging
growth to to in excited we back through growth we're our launch ST year. the the limited as have the for quarter, second the commercial expand cases CTO driver significant of already this and half innovative to of product full new the contributed potential a business about Tigereye launch be
expanding streamlining the additional for console imaging In combination new mainstream the our Lightbox in Pantheris developed the quarter, of with image-guided of of system. atherectomy clearance June, objective the our LV case the appeal our procedure, second platform. our We and platform our FDA clearance received we opening XXX(k) user in LV opportunities with with atherectomy X and Pantheris image-guided
incorporating and our device from system small-vessel with lesions to in features popliteal Pantheris is are suited larger the this our vessels LV ideally arteries SFA on in designed several SV, diameter, is millimeters application. Pantheris for to vessel three and device treat builds where performed. The above design LV procedures behind Pantheris PAD treat to of success knee the and majority the seven
clinical We platform. management months. limited systems Pantheris gain a and enhanced this It LV incorporates introduces the and than apposition LV proprietary a at experience offering. XX rotational higher balloon, launch plaque operates speeds large-vessel design plaque need the in the expect case management also for guidewire for significantly and to month, coming our to Pantheris for sites up in current without to initiated
a clinical launch Tigereye understand to setting new with device, prepare limited provides our performance benefits team for reliability period real-world the capabilities the sales As of important and product fully ST, the in clinical and full clinical national gauge launch.
the we about experience year. to We expand new launch to potential If Pantheris expand and as our are continued this full clinical in revenue on impact this all the to year. positively according launch half excited with two to to of goes their plan, these quarter second in look forward expect LV products commercial full fourth products, we of to updating you our commercial both
spin Lightbox reviews image is users portable our catheter X higher from Our high-speed degradation. complement for and perfect advanced catheters at the highly physician imaging speeds systems, new continues receive without and to to console rave allowing
Lightbox is our installed base responsible XX% approximately we volume, larger the of case X our expand support LXXX upside to legacy continue now we platform. providing opportunity for penetration of While significant this platform, as of
existing as in as accounts. Lightbox new X provide upgrade with is opportunities accounts being used well to efficiently engage
team, Lightbox we most on in While portable X in are the three clinical sold Lightbox systems brought procedures second console quarter. our performed support a by
PAD. Our Pantheris of SV or best-in-class treat be determine will within SV to treating market a diameter patients is CLI the to patient atherectomy Avinger. importance X- below-the-knee critical ischemia, can vessels. CLI very paramount outcomes amputation. many in when Pantheris of these the limb whom cases lesions most clinical Safety deliver continues performer able whether X-millimeter be is suffer patient for primarily severe avoid used to continues outcomes device, with small-vessel small And lesions form strong exceptional from of to and to
of we are is and case Pantheris target safely re-narrowing now arterial The real-time provided device to excited precise to SV and events with of SV for our preservation limb vessels. responsible adverse volume, that to design damage the by atherectomy for have the and market LV disease, features to imaging structures, flow our avoiding approximately precisely with the system. physicians extend XX% future this or blood allows new avoiding or the vascular restoring minimizing control Pantheris Pantheris above-the-knee while success driven
of clinical in and to evaluate treatment of inspired The setting. designed clinical IMAGE-BTK SV study, lesions our have unique the SV real-world a for Pantheris post-market below-the-knee compelling benefits Pantheris
XX the complete at clinical enrollment expect We patient continue study quarter. this set build to endpoint the post-procedure and to data months
U.S. Department enormous have study patients Medical Europe. Clinical backed presented for LINC Principal in Commenting Klinikum the Arnsberg at SV Center Michael Pantheris data on investigators in Class through major anatomy updated the Vascular in real-world of outstanding. Dr. from results Angiology Chief clinical by Symposium X promise challenging PAD Rutherford the at the recently of and and interim be IMAGE-BTK at to presentation for Lichtenberg, Director June Officer in continue treatment and his outcomes shows said the in X. conferences below-the-knee
XX% study in follow-up We XX at patency six- for IMAGE-BTK months events XXX% and from seen tremendous and XX-month outcomes with freedom freedom have point patients major TLR XX% enrollees. at across at adverse from this and the
option high balloon angioplasty, OCT-guided directional excellent an of As disease arteries results rates to atherectomy the XX% below-the-knee. as as compared in as address vascular restenosis support using type to these
the equally exceptional the has Lichtenberg, patient the the of to or luminal and data in addition been by for In of flow vessel impressive blood gain discussed safety durability Dr. opening study. outcomes
by a stenosis On to of study of reduction with adjunctive following a and the patients XX% This balloon of vessel. began alone to treatment representing blockage the or with Pantheris reduced following only in point stenosis XX therapy average, was at X% of further as the overall. XX% XX% the reduced a a use angioplasty an blockage this target treated in such optional XX% blockage
followed the results in study of becomes to disease Patients be of in results currently of luminal XX-month vasculature the the target treatment of combines the available approach, image-guided study our unprecedented as coming we therapy with value targeted atherectomy. have We the interim below-the-knee endpoint patients data which this gain anticipate advanced proprietary to directional are safety continue months. enrolled These the release XX in IMAGE-BTK emphasizing the and expect additional quarter. the our and in to clinical XX-patient achieving will enrollment of
to image-guided large bring the our coronary look we the future, platform growing excited benefits of and to market. the artery As we're to disease
arteries. coronary image-guided of product used the currently the superior application development expensive across complex solution a occlusions targets chronic Our total procedures uncertain to and first in
proprietary can leveraging we platform, only of market with image-guided in for system care By technology we first the our CTOs. this integrated believe the crossing standard and redefine fully coronary
focuses Our a combine and coronary coronary facilitate approach control catheter CTOs. guidance CTO and and OCT of number that physicians safely precise designs cross real-time with program an to on development allow integrated steerability low-profile efficiently to larger
our our properly help incorporate coronary a which Like to measurement prior balloons for stents placement, peripheral catheters, devices size to outcomes. precise is physicians critical or capability will optimal
device FDA distinction diagnostic CTO-crossing immediately a we clearance. diagnostic are coronary and such key upon for the therapeutic for with image-guided both access developing PAD reimbursement as is coronary existing capabilities would OCT codes. procedure This codes from An imaging
opportunity economic immediately an combined compelling for the with believe proposition. efficiency crossing an scenario catheter that OCT-guided designed provides highly a available for value attractive reimbursement We
Having we our primarily this efforts, activities R&D initiative. largely on coronary completed development are now focusing peripheral
significant advisory progress prototypes the through opinion feedback evolution board. design our key made leader valuable have and through our gained We of
in for next to successfully preparing we about past potential of FDA for year half round initiation standard of for next study we of of the are our CTOs. quarter We track remain file the first studies this animal clinical and a first for week. more are change Based on our this of groundbreaking in studies treatment experience excited believe IDE a KOL allow a to even completed product application the XXXX. center to with at on And animal round top of to-date we the care the coronary second an
and for sales first two new We tangible clearance making substantive progress peripheral our revenue on FDA important with base across capability application. fronts expanding development case our made over both our products and launch, and product of past building coverage advancing several the to the hires progress strategically limited devices quarter coronary securing
At to control deliver the operating and expenses adjusted EBITDA same improvement carefully significant time, we performance. in continue
broadening Pantheris our expand ST As creating appeal LV the drivers devices and commercial portfolio we we're back and new half the platform. Tigereye to look full for to usage of launch year, excited product of the to our our
our Lightbox activity coverage three our to the year. and field continue and commercial to account make to the look increase in through drive strategic new presence move base leverage as will to our remainder grow of imaging console investment we We new case capability user
important design The second learning coronary as first approach also a half to time of Phase gain is complete Phase III year. and of verification half in for validation we our application the the critically on II with our months of the the over year selection continue and valuable product development the FDA in design prepare and to next first an coming application IDE
financial Accounting this call the year. to to We throughout over our initiatives look to Nabeel Principal Officer us reporting our and And take I'd the at to progress results. through Subainati, forward these the turn against Officer point, like Financial
return for Nabeel? then I'll Q&A.